CN101331112B - 一种联苯乙酸盐及其制备方法与应用 - Google Patents
一种联苯乙酸盐及其制备方法与应用 Download PDFInfo
- Publication number
- CN101331112B CN101331112B CN2007800006970A CN200780000697A CN101331112B CN 101331112 B CN101331112 B CN 101331112B CN 2007800006970 A CN2007800006970 A CN 2007800006970A CN 200780000697 A CN200780000697 A CN 200780000697A CN 101331112 B CN101331112 B CN 101331112B
- Authority
- CN
- China
- Prior art keywords
- ammonia acetate
- biphenyl ammonia
- butantriol salt
- acetate butantriol
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- XTNRHLDLGNQMCW-UHFFFAOYSA-N acetic acid;1,1'-biphenyl Chemical compound CC(O)=O.C1=CC=CC=C1C1=CC=CC=C1 XTNRHLDLGNQMCW-UHFFFAOYSA-N 0.000 title abstract 3
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 32
- 239000003960 organic solvent Substances 0.000 claims abstract description 10
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 6
- GLTGDGIBGHPEKS-UHFFFAOYSA-N N.CC(O)=O.CCCC(O)(O)O.c1ccc(cc1)-c1ccccc1 Chemical compound N.CC(O)=O.CCCC(O)(O)O.c1ccc(cc1)-c1ccccc1 GLTGDGIBGHPEKS-UHFFFAOYSA-N 0.000 claims description 153
- 239000007924 injection Substances 0.000 claims description 131
- 238000002347 injection Methods 0.000 claims description 131
- 239000007788 liquid Substances 0.000 claims description 80
- 238000000034 method Methods 0.000 claims description 44
- 238000006243 chemical reaction Methods 0.000 claims description 38
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 11
- 229960000281 trometamol Drugs 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 230000036592 analgesia Effects 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 7
- 235000019441 ethanol Nutrition 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 239000008176 lyophilized powder Substances 0.000 claims description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- 150000001298 alcohols Chemical group 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 230000001754 anti-pyretic effect Effects 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 239000003507 refrigerant Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 12
- 230000000202 analgesic effect Effects 0.000 abstract description 4
- 229960000192 felbinac Drugs 0.000 abstract description 4
- ZAFJDLVZVINKSX-UHFFFAOYSA-N azane butane-1,1,1-triol Chemical compound N.CCCC(O)(O)O ZAFJDLVZVINKSX-UHFFFAOYSA-N 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004305 biphenyl Substances 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 42
- 230000008859 change Effects 0.000 description 41
- 238000012360 testing method Methods 0.000 description 40
- 241000699666 Mus <mouse, genus> Species 0.000 description 37
- 241000283973 Oryctolagus cuniculus Species 0.000 description 35
- 210000004204 blood vessel Anatomy 0.000 description 32
- 210000003205 muscle Anatomy 0.000 description 31
- 240000007711 Peperomia pellucida Species 0.000 description 26
- 239000000243 solution Substances 0.000 description 25
- 230000037396 body weight Effects 0.000 description 19
- 239000008354 sodium chloride injection Substances 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- -1 absorption carrier Substances 0.000 description 18
- 238000011179 visual inspection Methods 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 17
- 229910052739 hydrogen Inorganic materials 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 230000003387 muscular Effects 0.000 description 16
- 210000001087 myotubule Anatomy 0.000 description 16
- 206010002198 Anaphylactic reaction Diseases 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 15
- 230000036783 anaphylactic response Effects 0.000 description 15
- 208000003455 anaphylaxis Diseases 0.000 description 15
- 230000036407 pain Effects 0.000 description 15
- 206010018910 Haemolysis Diseases 0.000 description 13
- 230000008588 hemolysis Effects 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000002949 hemolytic effect Effects 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 230000000172 allergic effect Effects 0.000 description 10
- 238000010171 animal model Methods 0.000 description 10
- 208000010668 atopic eczema Diseases 0.000 description 10
- 210000005069 ears Anatomy 0.000 description 10
- 230000007794 irritation Effects 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 210000000689 upper leg Anatomy 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 238000012449 Kunming mouse Methods 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 210000003314 quadriceps muscle Anatomy 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 7
- 238000007689 inspection Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 240000006409 Acacia auriculiformis Species 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 206010014025 Ear swelling Diseases 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 241000283977 Oryctolagus Species 0.000 description 6
- 206010070834 Sensitisation Diseases 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 231100000403 acute toxicity Toxicity 0.000 description 6
- 230000007059 acute toxicity Effects 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000012362 glacial acetic acid Substances 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 240000001307 Myosotis scorpioides Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 150000003863 ammonium salts Chemical class 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000003118 histopathologic effect Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000581650 Ivesia Species 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 235000019633 pungent taste Nutrition 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 206010015719 Exsanguination Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical compound CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 208000004760 Tenosynovitis Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001721 carbon Chemical class 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000005261 decarburization Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 241001615463 Trichogenes Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/38—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings polycyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
反应症状 | 评价标准 |
0 | 过敏反应阴性(-) |
1-4 | 过敏反应弱阳性(+) |
5-10 | 过敏反应阳性(++) |
11-19 | 过敏反应强阳性(+++) |
20 | 过敏反应极强阳性(++++) |
兔号 | 左耳(给药侧) | 右耳(对照侧) |
1 | 血管轮廓较清晰,兔耳厚薄均匀,未见明显改变。 | 血管轮廓较清晰,兔耳厚薄均匀,未见明显改变。 |
3 | 进针部位血管内外侧的皮肤呈红色(0.1cm×0.5cm),血管轮廓较清晰,兔耳厚薄均匀,未见明显改变。 | 血管轮廓较清晰,兔耳厚薄均匀,未见明显改变。 |
4 | 血管轮廓较清晰,兔耳厚薄均匀,未见明显改变。 | 进针部位血管内外侧的皮肤呈红色(0.2cm×0.5cm),血管轮廓较清晰,兔耳厚薄均匀,未见明显改变。 |
6 | 血管轮廓较清晰,兔耳厚薄均匀,未见明显改变。 | 血管轮廓较清晰,兔耳厚薄均匀,未见明显改变。 |
兔号 | 左耳(给药侧) | 右耳(对照侧) |
2 | 血管轮廓较清晰,兔耳厚薄均匀,未见明显改变。 | 血管轮廓较清晰,兔耳厚薄均匀,未见明显改变。 |
5 | 进针部位血管内外侧的皮肤呈红色(0.1cm×0.2cm),血管轮廓较清晰,兔耳厚薄均匀,未见明显改变。 | 血管轮廓较清晰,兔耳厚薄均匀,未见明显改变。 |
7 | 进针部位血管内外侧的皮肤呈红色(0.1cm×0.2cm),血管轮廓较清晰,兔耳厚薄均匀,未见明显改变。 | 血管轮廓较清晰,兔耳厚薄均匀,未见明显改变。 |
8 | 进针部位血管内外侧的皮肤呈红色(0.1cm×0.2cm),血管轮廓较清晰,兔耳厚薄均匀,未见明显改变。 | 血管轮廓较清晰,兔耳厚薄均匀,未见明显改变。 |
动物号 | 左股四头肌(给药侧) | 右股四头肌(对照侧) |
1 | 注射部位表、深层肌肉组织质地富有弹性、光泽,无明显变化。 | 注射部位表、深层肌肉组织质地富有弹性、光泽,无明显变化。 |
3 | 注射部位表、深层肌肉组织质地富有弹性、光泽,无明显变化。 | 注射部位表、深层肌肉组织质地富有弹性、光泽,无明显变化。 |
4 | 注射部位表、深层肌肉组织质地富有弹性、光泽,无明显变化。 | 注射部位表、深层肌肉组织质地富有弹性、光泽,无明显变化。 |
6 | 注射部位表、深层肌肉组织质地富有弹性、光泽,无明显变化。 | 注射部位表、深层肌肉组织质地富有弹性、光泽,无明显变化。 |
动物号 | 左股四头肌(给药侧) | 右股四头肌(对照侧) |
2 | 注射部位表、深层肌肉组织质地富有弹性、光泽,无明显变化。 | 注射部位表、深层肌肉组织质地富有弹性、光泽,无明显变化。 |
5 | 注射部位表、深层肌肉组织质地富有弹性、光泽,无明显变化。 | 注射部位表、深层肌肉组织质地富有弹性、光泽,无明显变化。 |
7 | 注射部位表、深层肌肉组织质地富有弹性、光泽,无明显变化。 | 注射部位表、深层肌肉组织质地富有弹性、光泽,无明显变化。 |
8 | 注射部位表、深层肌肉组织质地富有弹性、光泽,无明显变化。 | 注射部位表、深层肌肉组织质地富有弹性、光泽,无明显变化。 |
动物号 | 左股四头肌(给药侧) | 右股四头肌(对照侧) |
1 | 肌肉组织结构正常,肌纤维排列整齐。 | 肌肉组织结构正常,肌纤维排列整齐。 |
3 | 肌肉组织结构正常,肌纤维排列整齐。 | 肌肉组织结构正常,肌纤维排列整齐。 |
4 | 肌肉组织结构正常,肌纤维排列整齐。 | 肌肉组织结构正常,肌纤维排列整齐。 |
6 | 肌肉组织结构正常,肌纤维排列整齐。 | 肌肉组织结构正常,肌纤维排列整齐。 |
动物号 | 左股四头肌(给药侧) | 右股四头肌(对照侧) |
2 | 肌肉组织结构正常,肌纤维排列整齐。 | 肌肉组织结构正常,肌纤维排列整齐。 |
5 | 肌肉组织结构正常,肌纤维排列整齐。 | 肌肉组织结构正常,肌纤维排列整齐。 |
7 | 肌肉组织结构正常,肌纤维排列整齐。 | 肌肉组织结构正常,肌纤维排列整齐。 |
8 | 肌肉组织结构正常,肌纤维排列整齐。 | 肌肉组织结构正常,肌纤维排列整齐。 |
组别 | 剂量(mg/kg) | 溃疡动物数/总动物数 |
联苯乙酸氨丁三醇盐 | 333 | 7/15 |
联苯乙酸 | 212 | 13/15 |
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007800006970A CN101331112B (zh) | 2006-10-23 | 2007-09-27 | 一种联苯乙酸盐及其制备方法与应用 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2006101229174A CN1944378A (zh) | 2006-10-23 | 2006-10-23 | 一种联苯乙酸氨丁三醇盐及其制备方法 |
CN200610122917.4 | 2006-10-23 | ||
PCT/CN2007/002830 WO2008049317A1 (en) | 2006-10-23 | 2007-09-27 | Biphenyl acetate, preparation and uses thereof |
CN2007800006970A CN101331112B (zh) | 2006-10-23 | 2007-09-27 | 一种联苯乙酸盐及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101331112A CN101331112A (zh) | 2008-12-24 |
CN101331112B true CN101331112B (zh) | 2012-03-21 |
Family
ID=38044057
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006101229174A Pending CN1944378A (zh) | 2006-10-23 | 2006-10-23 | 一种联苯乙酸氨丁三醇盐及其制备方法 |
CN2007800006970A Active CN101331112B (zh) | 2006-10-23 | 2007-09-27 | 一种联苯乙酸盐及其制备方法与应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006101229174A Pending CN1944378A (zh) | 2006-10-23 | 2006-10-23 | 一种联苯乙酸氨丁三醇盐及其制备方法 |
Country Status (3)
Country | Link |
---|---|
US (3) | US8653298B2 (zh) |
CN (2) | CN1944378A (zh) |
WO (1) | WO2008049317A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102093234B (zh) * | 2009-11-26 | 2014-06-18 | 福州乾正药业有限公司 | 一种二元酯酸的氨丁三醇盐化合物及其制备方法和药物应用 |
CN102885803A (zh) * | 2011-12-29 | 2013-01-23 | 广东中科药物研究有限公司 | 联苯乙酸氨丁三醇盐在制备治疗眼部炎症反应药物中的应用 |
CN103169653A (zh) * | 2013-03-13 | 2013-06-26 | 广东中科药物研究有限公司 | 一种联苯乙酸及其盐的新用途 |
WO2017156648A1 (zh) * | 2016-03-18 | 2017-09-21 | 广州诺威生物技术有限公司 | 一种用于抗炎的化合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0339176A1 (en) * | 1988-02-16 | 1989-11-02 | American Cyanamid Company | Suppository containing a non-steroidal anti-inflammatory medicament |
CN1073094A (zh) * | 1991-10-01 | 1993-06-16 | 美国氰胺公司 | 含联苯乙酸(felbinac)的药物组合物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2194144B (en) * | 1986-08-22 | 1990-04-25 | American Cyanamid Co | Stable pharmaceutical gel preparation |
US3624142A (en) * | 1964-09-10 | 1971-11-30 | Merck & Co Inc | Substituted biphenyl acetic acid derivatives |
US3784704A (en) * | 1972-10-13 | 1974-01-08 | American Cyanamid Co | Compositions of 4-biphenyl acetic acid and method of use |
US6139946A (en) * | 1997-05-30 | 2000-10-31 | Imation Corp. | Magnetic recording media incorporating a quaternary ammonium functional binder and magnetic pigment surface treated with compound having acidic and electron withdrawing functionalities |
US7074930B2 (en) * | 2001-11-06 | 2006-07-11 | Merck & Co., Inc | Amine salts of an integrin receptor antagonist |
WO2003048140A1 (fr) * | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Compose azole et utilisation medicinale de celui-ci |
US20050119314A1 (en) * | 2002-04-05 | 2005-06-02 | Sankyo Company, Limited | Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent |
JP2007515172A (ja) * | 2003-12-23 | 2007-06-14 | シェーリング コーポレイション | 無血清培地懸濁培養において安定なa549細胞株を生成するための方法 |
-
2006
- 2006-10-23 CN CNA2006101229174A patent/CN1944378A/zh active Pending
-
2007
- 2007-09-27 US US12/309,326 patent/US8653298B2/en active Active
- 2007-09-27 WO PCT/CN2007/002830 patent/WO2008049317A1/zh active Application Filing
- 2007-09-27 CN CN2007800006970A patent/CN101331112B/zh active Active
-
2012
- 2012-08-09 US US13/570,373 patent/US20130035505A1/en not_active Abandoned
-
2014
- 2014-02-25 US US14/189,711 patent/US20140179949A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0339176A1 (en) * | 1988-02-16 | 1989-11-02 | American Cyanamid Company | Suppository containing a non-steroidal anti-inflammatory medicament |
CN1073094A (zh) * | 1991-10-01 | 1993-06-16 | 美国氰胺公司 | 含联苯乙酸(felbinac)的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
US20140179949A1 (en) | 2014-06-26 |
US20130035505A1 (en) | 2013-02-07 |
CN1944378A (zh) | 2007-04-11 |
CN101331112A (zh) | 2008-12-24 |
WO2008049317A1 (en) | 2008-05-02 |
US20100016632A1 (en) | 2010-01-21 |
US8653298B2 (en) | 2014-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107970209A (zh) | 亲脂性药剂的改进的胃肠外制剂以及制备和使用其的方法 | |
CN103735500B (zh) | 盐酸他喷他多注射液及其制备方法 | |
CN105726522B (zh) | 厚朴酚在杀灭鱼类寄生原虫中的应用及其制剂 | |
CN103524427B (zh) | 一种三甲氧苄氨嘧啶半抗原制备方法及其应用 | |
CN101331112B (zh) | 一种联苯乙酸盐及其制备方法与应用 | |
CN103323592B (zh) | 高通量毒品毒物快速检测芯片及系统 | |
CN104474551A (zh) | 褪黑素磷脂复合物、其透皮给药制剂及其制备方法 | |
CN108463222A (zh) | 用于治疗疾病的杂环化合物 | |
CN101967142B (zh) | 噻唑酰胺类化合物及其在治疗恶性肿瘤中的药物用途 | |
MX2012010952A (es) | Forma cristalina de citrato de aldefanil, metodo de preparacion y uso del mismo. | |
CN104557909B (zh) | 3-酰氧基取代右旋去氧娃儿藤宁衍生物、其制法和药物组合物与用途 | |
CN101606950A (zh) | 一种小儿氨酚黄那敏颗粒及质量控制方法 | |
CN103301101B (zh) | 2-(2-氟-4-联苯基)-丙酸的新型药物组合物 | |
CN102335114B (zh) | 一种稳定的布洛芬精氨酸注射剂及其制备方法 | |
CN102125583A (zh) | 一种小儿氨酚黄那敏颗粒及质量控制方法 | |
CN1810794A (zh) | 脱水穿心莲内酯的制备工艺以及它们的药物组合物 | |
CN102344360B (zh) | 精氨酸右旋布洛芬的制备方法 | |
CN101168502B (zh) | 一种联苯乙酸氨丁三醇盐及其制备方法 | |
CN100360133C (zh) | 用于戒毒、镇痛的河豚毒素呼吸道给药制剂 | |
CN103655460B (zh) | 一种含氨曲南的注射用药物组合物及其制备方法和用途 | |
Chen et al. | Rate of Urinary Arsenic Excretion After Giving Acetarsone (“Stovarsol) and “Carbarsone” by Mouth. | |
CN100427484C (zh) | 2-甲氧基甲基-3-(3,4-二氯苯基)-8-氮杂双环[3.2.1]辛烷酒石酸盐 | |
CN100408571C (zh) | 穿心莲内酯三马来酸半酯及其盐和它们的药物组合物 | |
CN113069451B (zh) | 一种吡咯-2-磺酰胺化合物的制备方法及其在制备抗肿瘤药物中的应用 | |
CN102335169B (zh) | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗老年痴呆药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: YILING PHARMACEUTICAL CO. LTD., SHIJIAZHUANG Free format text: FORMER OWNER: GUANGDONG ZONK DRUG R+D LIMITED Effective date: 20121023 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510630 GUANGZHOU, GUANGDONG PROVINCE TO: 050035 SHIJIAZHUANG, HEBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121023 Address after: 050035 Shijiazhuang high tech Development Zone, Hebei Province, Tianshan Road, No. 238 Patentee after: Shijiazhuang Yiling Pharmaceutical Co., Ltd. Address before: 510630, Guangdong, Zhongshan, Guangzhou Avenue, Tangxia, B Road, building on the four floor Patentee before: Guangdong Zonk Drug R & D Limited |
|
TR01 | Transfer of patent right |
Effective date of registration: 20200716 Address after: No.23, Keji Road, economic development zone, Miyun District, Beijing 101500 Patentee after: Beijing Yiling Bioengineering Co.,Ltd. Address before: 050035 No. 238 Tianshan Avenue, Shijiazhuang hi tech Development Zone, Hebei, China Patentee before: Shijiazhuang Yiling Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210329 Address after: 050035 No. 238 Tianshan Avenue, Shijiazhuang hi tech Development Zone, Hebei, China Patentee after: Shijiazhuang Yiling Pharmaceutical Co.,Ltd. Address before: 101500 23 Keji Road, economic development zone, Miyun District, Beijing Patentee before: Beijing Yiling Bioengineering Co.,Ltd. |
|
TR01 | Transfer of patent right |